TRMT10A

Across TCGA pan-cancer cohorts, TRMT10A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TRMT10A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TRMT10A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TRMT10A is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where TRMT10A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRMT10A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	−0.375	<.001	11	view →
LUAD	Male	All	+0.573	<.001	9	view →
LSCC	Male	II,III,IV	+0.773	<.001	8	view →
HNSC	Male	IV	+0.451	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TRMT10A–CCRCC

Open the CCRCC breakdown →